Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Jaundice in pregnancy)
2,966 results
  • Impact of different glycaemic treatment targets on pregnancy outcomes in gestational diabetes. [Journal Article]
  • DMDiabet Med 2018 Aug 13
  • Abell SK, Boyle JA, … Teede HJ
  • CONCLUSIONS: Tight GDM treatment targets were associated with greater insulin use and no difference in primary birthweight outcomes. The service with tight targets had higher obstetric intervention, lower rates of reported hypoglycaemia, jaundice, respiratory distress and lower Apgar scores. High-quality interventional data are required before tight treatment targets can be implemented. This article is protected by copyright. All rights reserved.
  • Metformin for women who are overweight or obese during pregnancy for improving maternal and infant outcomes. [Review]
  • CDCochrane Database Syst Rev 2018 Jul 24; 7:CD010564
  • Dodd JM, Grivell RM, … Hague WM
  • CONCLUSIONS: There is insufficient evidence to support the use of metformin for women with obesity in pregnancy for improving maternal and infant outcomes. Metformin was, however, associated with increased risk of adverse effects, particularly diarrhoea. The quality of the evidence in this review varied from high to low, with downgrading decisions based on study limitations and inconsistency.There were only a small number of studies included in this review. Furthermore, none of the included studies included women categorised as 'overweight' and no trials looked at metformin in combination with another treatment.Future research is required in order to further evaluate the role of metformin therapy in pregnant women with obesity or who are overweight, as a strategy to improve maternal and infant health, alone or as an adjuvant to dietary and lifestyle advice.
  • Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: Diagnostic and management implications. [Journal Article]
  • JGJ Gastroenterol Hepatol 2018 Jul 10
  • Yeap SP, Harley H, … Hague WB
  • CONCLUSIONS: Early-onset or recurrent ICP, especially with previous spontaneous or OCS-induced episodes of cholestasis and/or familial cholestasis, may be attributable to transporter mutations, including biallelic mutations of one or more transporters. Response to standard therapies for ICP is often incomplete; BA sequestering therapy or naso-biliary drainage may be effective. Optimized management can produce good outcomes despite premature birth and evidence of fetal compromise.
  • Postpartum acute fatty liver of pregnancy: a case report. [Journal Article]
  • JMJ Med Case Rep 2018 Jun 01; 12(1):67
  • Al-Husban N, Al-Kuran O, Al Helou A
  • CONCLUSIONS: The clinical presentation of acute fatty liver of pregnancy is very variable and nonspecific. Skin rash can be a new presenting symptom of acute fatty liver of pregnancy. Immediate suspicion of the diagnosis, appropriate investigations, and urgent initiation of therapy in an intensive care unit and by a multidisciplinary team resulted in a good outcome with no adverse health consequences for our patient.
New Search Next